Objective: The relationship between microsatellite instability (MSI) and response to
neoadjuvant chemoradiation in rectal cancer is not well understood. Background: We …

Between 5% and 10% of patients with rectal cancer present with locally advanced rectal
cancer (LARC), and 10% of rectal cancers recur after surgery, of which half are limited to …

Background Total neoadjuvant therapy (TNT) improves tumor response in locally advanced
rectal cancer (LARC) patients compared to neoadjuvant chemoradiotherapy alone. The …

Prior reports have indicated that defective mismatch repair (MMR) has a favorable impact on
outcome in colorectal cancer patients treated with surgery, immunotherapy, or adjuvant …

Background Neoadjuvant radiotherapy (RT) has been shown to improve local control;
however, whether it can improve overall survival (OS) in locally advanced rectal cancer …

Background For patients with low-and intermediate-risk stage II/III rectal cancer, current
studies have reached a consensus that preoperative radiotherapy may be dispensed with …

Background Preoperative chemoradiotherapy (CRT) is the standard treatment for locally
advanced rectal cancer (LARC). However, CRT failed to impact metastatic recurrence and …

Background Although neoadjuvant radiotherapy is typically administered for locally-
advanced rectal cancer to reduce local recurrence (LR), its role for patients who present with …

Background Locally advanced colon cancer (LACC) is associated with surgical challenges
during R0 resection, increased postoperative complications, and unfavorable treatment …

Background With local recurrence of rectal cancer continuing to decrease, distant
recurrence is becoming a major concern, especially for patients with low-and intermediate …